 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- PRO1160 / ProfoundBio
Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1051;
P1/2
PK, immunogenicity, and antitumor activity will also be evaluated. The study is currently enrolling at sites in the US, with future enrollment in China planned.
- |||| PRO1160 / ProfoundBio
Also by @EJonasch : Phae 1/2 study of PRO1160 a CD70-directed ADC which we will be opening @ClevelandClinic (Twitter) - Jul 13, 2023
- |||||| PRO1160 / ProfoundBio
New P1 trial, P1/2 data, Metastases: .@EJonasch, of @MDAndersonNews, shares a phase 1/2 study evaluating PRO1160, a CD70-directed ADC in advanced solid tumors and hematologic malignancies #KCRS23 @kidneycan (Twitter) - Jul 13, 2023
- |||||| PRO1160 / ProfoundBio
P1/2 data: Dr. @EJonasch presented the phase 1/2 trial in progress with a new compound PRO1160 anti-CD70 antibody drug conjugate in solid tumors including RCC. #KCRS23 (Twitter) - Jul 13, 2023
- PRO1160 / ProfoundBio
Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies (Live; Virtual) - Jun 16, 2023 - Abstract #KCRS2023KCRS_43;
- ||| PRO1160 / ProfoundBio
Enrollment open, Metastases: PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001) (clinicaltrials.gov) - Apr 27, 2023
P1/2, N=134, Recruiting, Sponsor: ProfoundBio US Co.
The study is currently enrolling at sites in the US, with future enrollment in China planned. Not yet recruiting --> Recruiting
- |||| PRO1160 / ProfoundBio
New P1/2 trial, Metastases: PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001) (clinicaltrials.gov) - Feb 9, 2023
P1/2, N=134, Not yet recruiting, Sponsor: ProfoundBio US Co.
- |||| PRO1160 / ProfoundBio
Review: PRO1160https://www.adcreview.com/drugmap/pro1160-an-adc-directed-to-cd70/ (Twitter) - Jul 17, 2022
- PRO1160 / ProfoundBio
PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin lymphoma (Section 21) - Mar 9, 2022 - Abstract #AACR2022AACR_4004;
PRO1160 has the potential for an expanded therapeutic index. PRO1160 is being developed for the potential treatment of patients with CD70-expressing hematologic and solid tumor cancers.